Search results
Showing 1 to 9 of 9 results for lisocabtagene maraleucel
NICE is unable to make a recommendation about the use in the NHS of lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in adults. This is because Celgene did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA987
NICE is unable to make a recommendation on lisocabtagene maraleucel (Breyanzi) after 1 systemic treatment in adults when a stem cell transplant is unsuitable. This is because the company did not provide an evidence submission.
Show all sections
Sections for TA1083
Awaiting development Reference number: GID-TA11754 Expected publication date: TBC
In development Reference number: GID-TA11823 Expected publication date: TBC
Evidence-based recommendations on lisocabtagene maraleucel (Breyanzi) for treating relapsed or refractory large B-cell lymphoma in adults after first-line chemoimmunotherapy when a stem cell transplant is suitable.
In development Reference number: GID-TA11385 Expected publication date: 25 February 2026
In development Reference number: GID-TA11001 Expected publication date: TBC
Evidence-based recommendations on obecabtagene autoleucel (obe-cel; Aucatzyl) for treating relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in adults.
Green light for groundbreaking personalised cancer therapy that reprogrammes immune system
We've recommended an innovative one-off cell therapy that could give hundreds of lymphoma patients precious extra time with loved ones.